KIDS vs. ATRI, TMCI, SILK, FNA, SIBN, AORT, EMBC, MDXG, IRMD, and OFIX
Should you be buying OrthoPediatrics stock or one of its competitors? The main competitors of OrthoPediatrics include Atrion (ATRI), Treace Medical Concepts (TMCI), Silk Road Medical (SILK), Paragon 28 (FNA), SI-BONE (SIBN), Artivion (AORT), Embecta (EMBC), MiMedx Group (MDXG), Iradimed (IRMD), and Orthofix Medical (OFIX). These companies are all part of the "surgical & medical instruments" industry.
OrthoPediatrics (NASDAQ:KIDS) and Atrion (NASDAQ:ATRI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking and earnings.
OrthoPediatrics has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Atrion has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
Atrion has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.
69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 66.2% of Atrion shares are owned by institutional investors. 31.8% of OrthoPediatrics shares are owned by company insiders. Comparatively, 22.7% of Atrion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Atrion had 5 more articles in the media than OrthoPediatrics. MarketBeat recorded 6 mentions for Atrion and 1 mentions for OrthoPediatrics. Atrion's average media sentiment score of 0.03 beat OrthoPediatrics' score of 0.00 indicating that Atrion is being referred to more favorably in the news media.
OrthoPediatrics received 175 more outperform votes than Atrion when rated by MarketBeat users. Likewise, 64.54% of users gave OrthoPediatrics an outperform vote while only 55.84% of users gave Atrion an outperform vote.
OrthoPediatrics presently has a consensus target price of $42.50, indicating a potential upside of 36.83%. Given OrthoPediatrics' higher probable upside, analysts plainly believe OrthoPediatrics is more favorable than Atrion.
Atrion has a net margin of 11.46% compared to OrthoPediatrics' net margin of -14.10%. Atrion's return on equity of 8.07% beat OrthoPediatrics' return on equity.
Summary
Atrion beats OrthoPediatrics on 9 of the 17 factors compared between the two stocks.
Get OrthoPediatrics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KIDS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KIDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OrthoPediatrics Competitors List
Related Companies and Tools
